Maria Victoria Hernández, J. M. Blanco-Madrigal, Walter Alberto Sifuentes-Giraldo, Ricardo Blanco, Trinitario Pina, Eva Galíndez-Agirregoikoa, Vera Ortiz-Santamaria, Anne Riveros, Inmaculada Jiménez-Moleón, María Luisa Velloso-Feijoó, Natalia Palmou-Fontana, O. Maiz-Alonso, Santos Castañeda, J.A. Bernal, Jordi del Blanco-Barnusell, Catalina Gomez-Arango, Juan Ramon De Dios, Miguel A. González-Gay, Jordi Fiter, Marina de los Riscos, Patricia Carreira, Francisco Ortiz-Sanjuán, Javier Narváez, Alejandro Olivé, M. Carmen González-Vela, Mireia Moreno, Javier Llorca, Carmen Ordóñez, María J. Rodriguez-Valls, Javier Loricera, Leyre Riancho-Zarrabeitia, Vanesa Calvo-Río, [Ortiz-Sanjuán,F, Blanco,R, Riancho-Zarrabeitia,L, González-Vela,MC, Calvo-Río,V, Loricera,J, Palmou-Fontana,N, Pina,T, González-Gay,MA] Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander. [Castañeda,S] Hospital Universitario de La Princesa, IIS Princesa Madrid, Madrid. [Olivé,A, Riveros,A] Hospital Universitario Germans Trias i Pujol, Badalona. [Velloso-Feijoo,ML] Hospital Valme, Sevilla. [Narváez,J] Hospital Universitario de Bellvitge Hospitalet, Barcelona. [Jiménez-Moleón,I] Hospital San Cecilio, Granada. [Maiz-Alonso,O] HU Donostia, San Sebastián. [Ordóñez,C] HRU Carlos Haya, Málaga. [Bernal,JA] HGU, Alicante, Alicante. [Hernández,MV] Hospital Clinic of Barcelona, Barcelona. [Sifuentes-Giraldo,WA] Hospital Ramón y Cajal, Madrid. [Gómez-Arango,C, Galíndez-Agirregoikoa,E, Blanco-Madrigal,J] Hospital Universitario Basurto, Bilbao. [Ortiz-Santamaria,V] Hospital General Granollers, Granollers, Spain. [del Blanco-Barnusell,J] H Sant Jaume, Calella. [De Dios,JD] HU Álava, Vitoria. [Moreno,M] HU Parc Taulí, Sabadell. [Fiter,J] HU Son Espases, Palma de Mallorca, Mallorca. [de los Riscos,M, Carreira,P] Hospital Universitario 12 de Octubre, Madrid. [Rodriguez-Valls,MJ] Hospital de Jerez, Jerez. [Llorca,JL] Universidad de Cantabria, IDIVAL, Santander. CIBER Epidemiology and Public Health (CIBERESP), Santander Spain., Universitat de Barcelona, and Universidad de Cantabria
Adult-onset Still's disease (AOSD) is often refractory to standard therapy. Anakinra (ANK), an interleukin-1 receptor antagonist, has demonstrated efficacy in single cases and small series of AOSD. We assessed the efficacy of ANK in a series of AOSD patients.Multicenter retrospective open-label study. ANK was used due to lack of efficacy to standard synthetic immunosuppressive drugs and in some cases also to at least 1 biologic agent.Forty-one patients (26women/15 men) were recruited. They had a mean age of 34.414 years and a median [interquartile range (IQR)] AOSD duration of 3.5 [2-6] years before ANK onset. At that time the most common clinical features were joint manifestations 87.8%, fever 78%, and cutaneous rash 58.5%. ANK yielded rapid and maintained clinical and laboratory improvement. After 1 year of therapy, the frequency of joint and cutaneous manifestations had decreased to 41.5% and to 7.3% respectively, fever from 78% to 14.6%, anemia from 56.1% to 9.8%, and lymphadenopathy from 26.8% to 4.9%. A dramatic improvement of laboratory parameters was also achieved. The median [IQR] prednisone dose was also reduced from 20 [11.3-47.5] mg/day at ANK onset to 5 [0-10] at 12 months. After a median [IQR] follow-up of 16 [5-50] months, the most important side effects were cutaneous manifestations (n=8), mild leukopenia (n=3), myopathy (n=1), and infections (n=5).ANK is associated with rapid and maintained clinical and laboratory improvement, even in nonresponders to other biologic agents. However, joint manifestations are more refractory than the systemic manifestations., Dr MAG-G received grants/research supports from Abbott, MSD, and Roche, and had consultation fees/participation in company sponsored speaker?s bureau from Abbott, Pfizer, Roche, Janssen, Lilly, Bristol-Meiers, and MSD.; Dr FO-S received grants/research supports from Abbvie.; This work was also partially supported by RETICS Programs, RD08/0075 (RIER), and RD12/0009/0013 from Instituto de Salud Carlos III (ISCIII) (Spain).